Zeo ScientifiX, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended April 30, 2024
June 15, 2024 at 01:46 am IST
Share
Zeo ScientifiX, Inc. reported earnings results for the second quarter and six months ended April 30, 2024. For the second quarter, the company reported sales was USD 1.13 million compared to USD 0.845 million a year ago. Net loss was USD 1.4 million compared to USD 1.99 million a year ago. Basic loss per share from continuing operations was USD 0.23 compared to USD 0.27 a year ago.
For the six months, sales was USD 2.29 million compared to USD 1.92 million a year ago. Net loss was USD 2.44 million compared to USD 4.28 million a year ago. Basic loss per share from continuing operations was USD 0.39 compared to USD 0.61 a year ago.
Zeo ScientifiX, Inc. is a clinical-stage biopharmaceutical company. It develops biological therapeutics for the treatment of degenerative diseases and regenerative medicine. Its products are derived from perinatal sources and manufactured to retain the naturally occurring extracellular vesicles, hyaluronic acid, and proteins without the addition or combination of any other substance or diluent and an autologous non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood (RAAM Products). Its RAAM Products and related services are principally used in the health care industry, administered by doctors and clinics. The Companyâs product, Zofin (Organicell Flow), is an acellular, biologic therapeutic derived from perinatal sources and is manufactured to retain naturally occurring microRNAs. Patient Pure X, its autologous product, is a non-manipulated biologic containing the nanoparticle fraction from a patientâs own peripheral blood.